These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 38150961)
1. Discovery of a CB Yang W; Gong X; Sun H; Wu C; Suo J; Ji J; Jiang X; Shen J; He Y; Aisa HA Eur J Med Chem; 2024 Feb; 265():116048. PubMed ID: 38150961 [TBL] [Abstract][Full Text] [Related]
2. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB Bouma J; Broekhuis JD; van der Horst C; Kumar P; Ligresti A; van der Stelt M; Heitman LH Biochem Pharmacol; 2023 Dec; 218():115924. PubMed ID: 37972874 [TBL] [Abstract][Full Text] [Related]
3. Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents. Bi GH; Galaj E; He Y; Xi ZX Addict Biol; 2020 Jul; 25(4):e12783. PubMed ID: 31215752 [TBL] [Abstract][Full Text] [Related]
4. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692 [TBL] [Abstract][Full Text] [Related]
5. (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB González-Mariscal I; Carmona-Hidalgo B; Winkler M; Unciti-Broceta JD; Escamilla A; Gómez-Cañas M; Fernández-Ruiz J; Fiebich BL; Romero-Zerbo SY; Bermúdez-Silva FJ; Collado JA; Muñoz E Pharmacol Res; 2021 Jul; 169():105492. PubMed ID: 34019978 [TBL] [Abstract][Full Text] [Related]
6. Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action. Chaves YC; Genaro K; Crippa JA; da Cunha JM; Zanoveli JM Metab Brain Dis; 2021 Apr; 36(4):639-652. PubMed ID: 33464458 [TBL] [Abstract][Full Text] [Related]
7. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803 [TBL] [Abstract][Full Text] [Related]
9. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240 [TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects. Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca Xia KK; Shen JX; Huang ZB; Song HM; Gao M; Chen DJ; Zhang SJ; Wu J Acta Pharmacol Sin; 2019 Mar; 40(3):410-417. PubMed ID: 30202013 [TBL] [Abstract][Full Text] [Related]
13. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363 [TBL] [Abstract][Full Text] [Related]
14. Xie2-64, a novel CB Jordan CJ; Feng ZW; Galaj E; Bi GH; Xue Y; Liang Y; McGuire T; Xie XQ; Xi ZX Neuropharmacology; 2020 Oct; 176():108241. PubMed ID: 32712273 [TBL] [Abstract][Full Text] [Related]
15. CBD Versus CBDP: Comparing In Vitro Receptor-Binding Activities. Haghdoost M; Young S; Holloway AK; Roberts M; Zvorsky I; Bonn-Miller MO Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062976 [TBL] [Abstract][Full Text] [Related]
16. Cannabidiol attenuates aggressive behavior induced by social isolation in mice: Involvement of 5-HT1A and CB1 receptors. Hartmann A; Lisboa SF; Sonego AB; Coutinho D; Gomes FV; Guimarães FS Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109637. PubMed ID: 31054943 [TBL] [Abstract][Full Text] [Related]
17. Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. Mori MA; Meyer E; da Silva FF; Milani H; Guimarães FS; Oliveira RMW Eur J Neurosci; 2021 Mar; 53(6):1738-1751. PubMed ID: 33522084 [TBL] [Abstract][Full Text] [Related]
18. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Campos AC; Moreira FA; Gomes FV; Del Bel EA; Guimarães FS Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3364-78. PubMed ID: 23108553 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563 [TBL] [Abstract][Full Text] [Related]
20. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]